NetScientific PLC shares rose on Monday after the company said that its portfolio company PDS Biotechnology Corp. has successfully completed an end-of-Phase-2 meeting with the U.S. Food and Drug Administration regarding the combination of its treatment with Merck & Co.'s therapy for papillomavirus carcinoma.
Shares at 1307 GMT were up 0.05 pence, or 13%, at 0.5 pence.
The life-sciences and technology investment company said that PDS has received guidance from FDA on key elements to submit a biologics license application for its PDS0101 asset treatment.
The end-of-Phase-2 meeting was to determine the safety of proceeding to the last phase of the study and identify any additional information necessary to support a marketing application for the uses under investigation.
The combined therapies are targeting the treatment of unresectable, recurrent and metastatic human-papillomavirus-16-positive head-and-neck squamous-cell carcinoma, the company added.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.